Switching multiple sclerosis patients with breakthrough disease to second-line therapy (Q33815455)

29 July 2017

title

Switching multiple sclerosis patients with breakthrough disease to second-line therapy (English)

1 reference

29 July 2017

0 references

12

Eric Vittinghoff

0 references

Emmanuelle Waubant

object named as

Emmanuelle Waubant

13

1 reference

29 July 2017

3

Alberto Gajofatto

1 reference

29 July 2017

6

Bruce A Cree

1 reference

29 July 2017

author name string

Tamara Castillo-Trivino

1

1 reference

29 July 2017

Ellen M Mowry

2

1 reference

29 July 2017

Dorothee Chabas

4

1 reference

29 July 2017

Elizabeth Crabtree-Hartman

5

1 reference

29 July 2017

Douglas S Goodin

7

1 reference

29 July 2017

Ari J Green

8

1 reference

29 July 2017

Darin T Okuda

9

1 reference

29 July 2017

Daniel Pelletier

10

1 reference

29 July 2017

Scott S Zamvil

11

1 reference

29 July 2017

language of work or name

English

0 references

publication date

3 February 2011

1 reference

29 July 2017

1 reference

29 July 2017

volume

6

1 reference

29 July 2017

issue

2

1 reference

29 July 2017

page(s)

e16664

1 reference

Creative Commons Attribution 4.0 International

29 July 2017

copyright license

start time

3 February 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Course of relapsing-remitting multiple sclerosis before, during and after natalizumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3033401

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3033401

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3033401

Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3033401

Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3033401

Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3033401

Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3033401

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3033401

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3033401

Clinical characteristics of responders to interferon therapy for relapsing MS.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3033401

Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3033401

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3033401

Effects of cyclophosphamide on the development of malignancy and on long‐term survival of patients with rheumatoid arthritis a 20‐year followup study

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3033401

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

4 July 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0016664

Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0016664

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0016664

A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0016664

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0016664

Combination therapy in multiple sclerosis

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21304907

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Natalizumab dosage suspension: are we helping or hurting?

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21304907

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1371/JOURNAL.PONE.0016664

1 reference

29 July 2017

0 references

1 reference

29 July 2017

1 reference